Aviva PLC Mirati Therapeutics, Inc. Transaction History

Aviva PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$144.0 - $179.73 $1.01 Million - $1.27 Million	-7,047 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$158.92 - $221.61 $102,185 - $142,495	-643 Reduced 8.36%	7,047 $1.21 Million
Q4 2020 Feb 10, 2021	SELL	$162.05 - $240.27 $1.01 Million - $1.5 Million	-6,232 Reduced 44.76%	7,690 $1.69 Million
Q3 2020 Nov 12, 2020	SELL	$113.26 - $167.27 $678,314 - $1 Million	-5,989 Reduced 30.08%	13,922 $2.31 Million
Q2 2020 Aug 13, 2020	SELL	$72.01 - $120.39 $1.93 Million - $3.23 Million	-26,816 Reduced 57.39%	19,911 $2.27 Million

Q1 2020 May 14, 2020	BUY	$69.78 - $116.21 $3.26 Million - $5.43 Million	46,727 New	46,727 $3.59 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.